Physician profile
Michael W Mendelson
NPI 1043323835
$2,054.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $542 · 2021: $179 · 2022: $29.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $458.98 | 2019-2021 | |
| Amarin Pharma, INC. | $278.28 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $236.29 | 2019 | |
| Allergan, INC. | $203.16 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $181.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $169.36 | 2019-2020 | |
| Grifols USA, LLC | $127.29 | 2019 | |
| Amgen INC. | $124.77 | 2019 | |
| Insmed, INC. | $121.34 | 2021 | |
| Glaxosmithkline, LLC. | $59.76 | 2019 | |
| Novo Nordisk INC | $36.30 | 2021-2022 | |
| Electromed, INC. | $23.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.59 | 2020 | |
| Advanced Respiratory, INC | $16.03 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.